SciELO - Scientific Electronic Library Online

 
vol.46 issue5Doctors, lawyers and pharmaceutical industry on health lawsuits in Minas Gerais, Southeastern BrazilRisk and sanitary safety: analysis on medical product reprocessing in hospitals in Salvador, Northeastern Brazil author indexsubject indexarticles search
Home Page  

Revista de Saúde Pública

Print version ISSN 0034-8910

Rev. Saúde Pública vol.46 n.5 São Paulo Oct. 2012

http://dx.doi.org/10.1590/S0034-89102012000500005 

ORIGINAL ARTICLES

 

Legal decisions on access to medicines in Pernambuco, Northeastern Brazil

 

Decisiones judiciales sobre acceso a los medicamentos en Pernambuco

 

 

Artur StamfordI; Maísa CavalcantiII

IDepartamento de Teoria Geral do Direito e do Direito Privado. Faculdade de Direito do Recife. Universidade Federal de Pernambuco. Recife, PE
IINúcleo de Pesquisa em Inovação Terapêutica. Programa de Pós-Graduação em Inovação Terapêutica. Universidade Federal de Pernambuco. Recife, PE

Correspondence

 

 


ABSTRACT

OBJECTIVE: To analyze decisions from the legal system concerning the population's access to medicines within the Brazilian Public Health System through judicial channels, with regard to decision-making criteria and possible political and economic pressure.
METHODS: This was a descriptive retrospective study on documents with a quantitative and qualitative approach. Data were gathered from the State of Pernambuco Superintendency for Pharmaceutical Care, and the data sources used were 105 lawsuits and administrative reports between January and June 2009. It was ascertained which medications have a patent or patent request in the database of the Brazilian Patent Office (INPI), in order to identify the frequency with which patents feature in lawsuits. The data obtained were classified according to Anatomical and Therapeutic Chemical System. To analyze the judicial decisions, the theory of autopoietic social systems was used.
RESULTS: There were lawsuits involving 134 medications, with an estimated value of R$ 4.5 million for attending the treatments requested. 70.9% of the medications had a patent or a patent request and they were concentrated in three therapeutic classes: antineoplastic and immunomodulating agents; digestive tract and metabolism; and sensory organs. Six central ideas within judges' decision-making criteria were identified (the federal constitution and medical prescriptions), along with pressure between the legal, economic and political systems concerning access to medications.
CONCLUSIONS: The analysis on judicial decisions based on the theory of autopoietic social systems made it possible to identify mutual stimulation (dependency) between the legal system and other social systems in relation to the issue of citizens' access to medications. This dependency was represented by the federal constitution and intellectual property. The federal constitution and medical prescription were identified as decision-making criteria in lawsuits. Intellectual property represented possible political and economic pressure, especially in cases of launching medications into the market.

Descriptors: Pharmaceutical Services. Judicial Decisions. Intellectual Property of Pharmaceutic Products and Process. Equity in Access. Health Law.


RESUMEN

OBJETIVO: Analizar las decisiones del sistema jurídico sobre el acceso de la población a medicamentos en el Sistema Nacional de Salud de Brasil por vía judicial con relación a criterios de decisión y eventuales presiones políticas y económicas.
MÉTODOS: Estudio documentado descriptivo y retrospectivo de abordaje cualitativo y cuantitativo. La colecta de datos fue realizada en la Superintendencia Estatal de Asistencia Farmacéutica de Pernambuco, utilizándose como fuentes de datos 105 acciones judiciales e informes administrativos de enero a junio de 2009. Se verificaron los medicamentos con pedido o Patente en el banco de datos del Instituto Nacional de Propiedad Industrial para identificar la frecuencia de las patentes en las acciones judiciales. Los datos obtenidos se clasificaron de acuerdo al Sistema Anatómico y Terapéutico Químico. Para análisis de las decisiones judiciales, se utilizó la teoría de los sistemas sociales autopoiéticos.
RESULTADOS: Las acciones judiciales totalizaron 134 medicamentos con valor estimado de R$ 4,5 millones para atender a los tratamientos solicitados; 70,9% de los medicamentos estaban con Patente o pedido y se concentraron en tres clases terapéuticas: antineoplásicos y moduladores inmunológicos, aparato digestivo y metabolismo, órganos de los sentidos. Se identificaron seis ideas centrales con los criterios de decisión de los magistrados (Constitución Federal y prescripción médica) y las presiones entre los sistemas de derecho, de la economía y de la política con relación al acceso a medicamentos.
CONCLUSIONES: El análisis de las decisiones judiciales fundamentadas en la teoría de los sistemas sociales autopoiéticos permitió identificar las estimulaciones mutuas (dependencias) entre el sistema de derecho y demás sistemas sociales con relación al asunto del acceso de los ciudadanos a los medicamentos. Esas dependencias fueron representadas por la Constitución Federal y por la propiedad intelectual. La Constitución Federal y la prescripción médica fueron identificadas como criterio de decisión en las acciones judiciales. La propiedad intelectual representó eventuales presiones políticas y económicas, especialmente, en los casos de lanzamiento de medicamentos en el mercado.

Descriptores: Servicios Farmacéuticos. Decisiones Judiciales. Propiedad Intelectual de Productos y Procesos Farmacéuticos. Equidad en el Acceso. Derecho Sanitario.


 

 

INTRODUCTION

The International Covenant on Economic, Social and Cultural Rights, of 1966, recognized the right of every person to enjoy the highest level of health and highlighted the population's access to medication through referring to its participation in scientific progress and its benefits.ª Although late, the publication of the Alma-Ata Declaration, in 1978, was the first international mention of the importance of medications that are essential to primary healthcare.b

When countries in Latin America and Central America recognized this right in their federal constitutions, they began to face a frequent problem: the rising number of lawsuits against governments, demanding that medications that were not in the list of essential medications for the public health systems should be supplied.7

The number of lawsuits against local governments can reach close to seven thousand per year in Brazil, representing annual expenditures of up to R$ 60.4 million ($ 60.4 million).3,4,11,21 Concession of medications is considered to be a means of judicialization of healthcare policy.5 Researchers have suggested that judicial decisions do not take into account the possibility that there may be influences external to the political system capable of interfering in the incorporation of therapeutic innovations within the Brazilian National Health System (Sistema Único de Saúde, SUS), such as pressure from the pharmaceutical industry or from doctor and patient associations.5,13,21

The objective of this study was to analyze decisions from the legal system concerning the population's access to medications within SUS through judicial channels, with regard to decision-making criteria and possible political and economic pressure.

 

METHODS

This was a descriptive retrospective study on documents with a quantitative and qualitative approach. Cost reports (spreadsheets with estimated total values of the annual acquisition of each medication and the total number of registered patients for each medication) and interlocutory decisions from 105 lawsuits that demanded that medications should be supplied by the Pernambuco State Health Department, between January and June 2009, were analyzed.

A form was used to gather the variables of the cost report in the quantitative stage: commercial name of the medication, common designation of the drug in Brazil, name of the producing laboratory, total acquisition cost of each medication, and total number of registered patients for each medication.

The medications were classified in accordance with the Anatomical and Therapeutic Chemical System of the World Health Organization. It was ascertained which medications have a patent or patent application in the database of the Brazilian Industrial Property Office (Instituto Nacional de Propriedade Industrial, INPI).

The data were analyzed using the Excel® software, version 2007, and the variables were presented as simple frequencies.

The interlocutory decisions of the magistrates of the Pernambuco Court of Justice were analyzed qualitatively from a simple random sample, using the criterion of sampling until saturation.5 The technique of collective subject discourse, similar to what was described in the study of Marques & Dallari,12 was used to organize and tabulate the qualitative data. The main arguments mentioned by the magistrates were transcribed from each interlocutory decision. Key expressions were extracted and, from the similarity between them, a synthesis of the discourse was produced, from which the central ideas were identified.9

Theoretical Framework

The Luhmann10 theory of autopoietic social systems was used to identify the decision criteria and describe the relationship between law, politics and economy.

This theory has three theoretical contributions: shape theory, differentiation theory and evolution theory.10 The present study does not intend to detail these contributions, but a few concepts need to be outlined in order to understand its application to health issues, which may be communicated in political, economic, juridical or scientific shape.

The Luhmann social theory takes communication (selection process through differentiation) to be the minimum unit, or cell, of society. Another theoretical basis is autopoiesis: production (poiesis) by itself (auto). Even though this concept has its origin in biology, Luhmann made the required adaptation of autopoiesis to the theory of society by identifying communication as the social element responsible for producing and reproducing society. 10

According to Luhmann, the elements (communications) are created within autopoietic social systems, and establish connections among themselves through operational closure. This closure enables recursive (cyclic) production of sense, i.e. the communication acts on itself (self-referential network). Thus, communications are not imported from the environment (surroundings). On the contrary, they are processed (produced) inside the social system, according to their own criteria.8,10

However, social systems do not ignore stimuli from the surroundings, but create reciprocal dependence between the social system and its environment. This relationship of dependence is called structural linkage and, through it, social systems choose the communication stimuli that come from the environment.8,10

As some communications reach a high level of complexity, social systems with specific functions are formed, for instance the legal system. In accordance with the specific function of each social system, there is an exclusive binary language code that allows each system to autopoietically choose the communication stimuli from the surroundings. Each binary code has a positive and a negative version. For instance, the legal system operates with the code of legal/illegal language, and the political system with a can/cannot code. Thus, the code leaves the communication stimuli susceptible to acceptance or rejection. As a result, the meaning will be maintained or changed within the social system, thus allowing its autopoiesis (Figure 1). 8,10

 

 

Operationally closed social systems do not import elements straight from the environment. However, they are cognitively open to the environment, and observe (hetero-reference) without risking their own identity. 8,10

Social evolution depends on communicative performance. Moreover, action by organizations within the social system is the sine qua non condition for attaining this evolution, since only organizations are capable of communicating with their surroundings. For these organizations, communication of decisions is the operational baseline.10

 

RESULTS

The lawsuits analyzed reached around R$ 4.5 million during the year; 70.9% of the medications had a patent in Brazil or a patent request in the INPI, thus characterizing market monopoly. Among these medications, 73.7% were concentrated in three therapeutic classes (Table 1), which represented 77.7% of the financial resources directed towards addressing these lawsuits (Table 2).

Eight pharmaceutical companies were the manufacturers of 80% of the medications with a patent or a patent request in the INPI; 90.95% of the financial resources of the Pernambuco State Health Department for the acquisition of these medications related to seven pharmaceutical laboratories.

The mean acquisition value of each medication for annual treatments belonging to the classes of antineoplastic and immunomodulatory agents ranged from R$ 37,000 to R$ 193,000. The values in the sensory organs class ranged from R$ 18,000 to R$ 30,000.

Fifty interlocutory decisions were analyzed by 35 magistrates: 20 judges and 15 appeal judges of the Pernambuco Courts of Justice in the judicial districts of the state capital and the interior of the state.

Six discourse syntheses were produced and their respective central ideas were identified through the magistrates' decision criteria, as follows: 1: Insufficient financial resources in the public budget cannot be used as an argument by the State to justify non-implementation of actions and health services required by citizens; 2: The health of human beings is their greatest asset and deserves protection from the State through implementation of public policies capable of ensuring enough protection for human beings; 3: Access to high-cost medications for treating chronic diseases in citizens who do not have financial conditions allowing them to purchase such medications is the State's duty; 4: The public authority has the obligation to promote universal, comprehensive and free access to each and every treatment prescribed by a doctor, using all available technological means; 5: The State has a duty to provide medication prescribed by a trained doctor, and whether it was previously included in the government's list of medications is irrelevant; 6: The State can suggest an alternative to the medication prescribed by a doctor, as long as there is documental proof of the equivalence of its effectiveness.

 

DISCUSSION

The results reflected similarities with the global market for medication sales in the United States, in which the therapeutic classes of antineoplastic and immunomodulatory agents were among the ten most sold medications. Three medications in this therapeutic class appeared in the global ranking of the ten most sold products.c

Other studies have also found this therapeutic class to be among the classes most demanded judicially.11,21

The estimated values of the annual treatments of the therapeutic classes most demanded judicially were burdensome. Comparison between these values and the gross domestic product (GDP) per capita of Brazil (almost R$ 17,500 in 2010)d and the average monthly income of Brazilian families (R$ 2,763.47),e corroborates the arguments of the legal decisions concerning the insufficiency of purchasing power among the population for buying these medications. The majority of the Brazilian population cannot afford these costly treatments without resorting to SUS. However, it is necessary to analyze this situation of high prices, which may be associated with the patents of the medications. Among the medications demanded judicially, 70.9% had a patent or a patent request in the INPI.

As also stated by Reis & Bermudez,15 the present study allowed the observation that just a few companies concentrate the majority of the billing relating to active pharmaceutical agents in Brazil. There is a monopoly of production and trading of medications and a market oligopoly of beneficial items that are essential for human health. In this context, a debate on the intellectual property of products and pharmaceutical processes is justified.

Luhmann10 stated that property is valued in term of money and is present in all economic transactions, and that it can only be properly understood from an overall social perspective, as a mechanism of structural linkage. According to Tachinardi,19 intellectual property protection is a mechanism of power and an instrument for controlling the market so as to reduce the uncertainties of innovators, i.e. moving towards a political and economic focus rather than a legal focus. Behind the discourse stating that the objective of intellectual property is to stimulate invention, there is a real economic objective: financial appropriation of scientific knowledge. Proner14 stated that technological dependence is a factor of economic and political subordination, and that, when allied with science, it creates an unquestionable source of power.

In this situation of judicialization of health policy and intellectual property, one relevant issue is the second-order effects of judicial decisions, given that the decisions set precedents and affect the expectations of private agents, with positive or negative consequences for society. The juridical system needs to consider the possibility that its decisions may bring predictability from an economic viewpoint. The procedural-constitutional system is leading towards greater linkage of Brazilian judges to the precedents of higher courts, such as the mechanism of binding precedents.20

The operations of the legal system were seen to be recursive. Many decisions referred to others from state courts, the Federal Court or from the Federal Supreme Court. In addition, precedent no. 18 of the Pernambuco Court of Justice itself was referred to on many occasions: "The State has a duty to provide medications that are essential for treating serious illnesses, for needy citizens, without charging them, even if such medications are not present on the official list".

The judicial system kept its exclusiveness through its recursiveness of communication. The operations came from previous decisions from other courts - the Brazilian Federal Constitution (articles 5 and 196) - and decisions from other courts, thereby creating the conditions for the subsequent operation.17

Wang 22 stated that all the decisions from the Federal Supreme Court that were analyzed granted the medication requested and that references to precedents from the court's own decisions were frequently made, as observed in the present study.

The Constitution was the judges' decision-making criterion (central ideas 1, 2 and 3), and this has already been observed in an international study concerning this issue.6 Based on the theoretical framework used in the present study, the Constitution was a relevant structural linkage. The Constitution is an operative precondition for the political system, i.e. a preset means for decision-making that brings legitimacy. For the judicial system, it played the role of assuring normative expectations, thus increasing the possibility of implementation of the public policies announced in its text.17

Through this, it was possible to demonstrate the relationships between access to medications, the law, politics and the economy. The legal system rejected the communication from the political system regarding the limited financial resources of the health budget (central ideas 1 and 2). In the light of the theory of autopoietic social systems,10 it was observed that the legal system, which operated with the exclusive binary code of 'legal/illegal' in relation to its surroundings, was selective. No cognitive opening10 of this social system in the communication process relating to the limited financial resources for implementing the right to health was observed. Such a cognitive opening is important because it influences the implementation of the right to health, especially regarding access to medications. 7

On the other hand, there was a cognitive opening of the legal system in relation to central idea 6, with acceptance of the communication about selection of medications through pharmaceutical attendance (an organization in the political system). However, central idea 5 indicated the opposite, i.e. rejection of the same communication. This mutual dependency (structural linkage) between the two social systems for achieving the right of access to medications increased the risk that one system might interfere with the other.10

Another decision criterion of the legal system was medical prescription, which was present in central ideas 4 and 5 and has been reported in other studies. f,g This criterion allowed observance of the structural linkage between the decisions of the legal, economic, scientific and political systems.

Pharmaceutical attendance needs to select communications from the economic and scientific systems, considering the great quantity of medications available and the low therapeutic gain from those released on the market.1

On the other hand, a decision by this organization not to include a medication released onto the market, in the SUS list, may stimulate the legal and economic systems. This will be stimulated to a greater degree if medications under patent protection are involved. This may involve use of means of dissemination10 (advertising) and symbolically generalized means of communication10 (the power of doctors and of patients' associations),f,g in order to increase the chances of communication acceptance.8 Communication about new medications on the market is capable of reciprocally stimulating social systems via structural linkage. The decisions of the legal system can influence the decisions of pharmaceutical attendance regarding inclusion or non-inclusion of a new medication in the SUS list via structural linkage (Figure 2).

Cruz & Correia5 warned that there was a need to take into consideration the risks and mistakes that jurisdictional action might cause, as a result of possible communicational distortions of the pharmaceutical industry. Such distortions can be noticed in the analysis performed by Barros,1 in which regression of the therapeutic gain of the 1,284 medications released onto the market between 1990 and 2004 was observed. The therapeutic gain decreased from 31% to 23% over this period, according to an evaluation by the United States Food and Drug Administration (FDA).

Serra-Sastre & McGuire 18 stated that the demand for healthcare services is a reflection from doctors' decisions, not from the final consumer's decision, because of the asymmetry of information in the doctor-patient relationship. The dissemination of medications on the market is proportionally related to medical prescriptions for the new medications, for patients.

Analysis on the dissemination of new medication should be made from two aggregation levels: the market and the individual perspective of the decision-maker. At the individual level, the focus is on comprehension of the decision-maker's behavior. In countries that have public health systems, the price of medication will probably not be a relevant variable to be considered by the doctor at the time of making the prescription (decision process), since acquisition of the medication will be the government's responsibility. However, the market demand will be affected by the prices of the products, which are targets of negotiation between the manufacturer and the government. The price is a relevant variable for the market, but not for the individual decision.18

Berndt et al2 observed the degree of influence that widespread use of a medication has on doctors, through safety and effectiveness information. The fact that a medication is widely used on the market may suggest that it has greater effectiveness and low side effects and risks. Despite the availability of alternatives on the market, use of a certain medication may predominate, and not necessarily the most effective or safest one. As more people start to use the new product, communication increases, which accelerates the pace at which other people start to know about the existence of the medication.

The dissemination rates for medication brands depends indirectly on the attributes of the medication and directly on the previous sales of the therapeutic class, which reflects the learning and communication between doctors and patients. The accumulated sales on the market may affect the demand, from perception of the quality attributes of the product (effectiveness and safety), thus accelerating its dissemination rate.2

Experimentation and learning are central elements driven by the doctor's experience in both of these diffusion models. The characteristic attribute of the diffusion process is the combination of many pressures acting together, especially at the information level. The demand for new medications remains underexplored due to the diversity of pressures and interests that interact on the market.18

Regarding these pressures, the present study highlighted that intellectual property is the structural linkage that allowed reciprocal stimulations between different social systems involved in access to medications. The quality of patents needs to be evaluated and improved based on determining higher requirements for novelty and non-obviousness. Governments need to ensure prior opposition, such that applications that do not meet the rigor of these requirements will not be granted.16

The analysis on the juridical decisions, based on Luhmann's theory of social systems made it possible to identify the mutual stimulations (dependencies) between the legal system, and its surroundings concerning access to medication through SUS. These structural linkages (dependencies) were represented by the Federal Constitution and by intellectual property. It can be suggested that the legal system should use the "therapeutic gain" of the medication as a decision-making criterion, in replacement for the medical prescription, so as to ensure scientifically proven benefits from treatments for citizens and mitigate the judicialization of health policy.

The theory of autopoietic social systems allows multiple descriptions of society from different observers and do not aim to determine any causal relationship.10 The limitation of the present study is that it did not allow definition of the cause of judicialization of health policy.

More studies will be necessary in order to better comprehend the manner of dissemination and the demand for new medications, as well as access to them through SUS.

 

ACKNOWLEDGMENTS

To the pharmacist Jósé de Arimatea da Rocha Filho and his team, at the Supervisory Office for Pharmaceutical Care of the Health Department of the State of Pernambuco, for access to the data used in the study.

 

REFERENCES

1. Barros JAC. Antigas e novas questões: Enfrentando uma conjuntura desfavorável. In: Barros JAC, editor. Os fármacos na atualidade: antigos e novos desafios. Brasília: Anvisa; 2008. p.67.         [ Links ]

2. Berndt ER, Pindyck RS, Azoulay P. Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs. J Ind Econ. 2002;51(2):243-70.         [ Links ]

3. Biehl J, Petryna A, Gertner A, Amon JJ, Picon PD. Judicialization of the right to health in Brazil. Lancet. 2009;373(9682):2182-4. DOI:10.1016/S0140-6736(09)61172-7        [ Links ]

4. Chieffi AL, Barata RB. Judicialização da política pública de assistência farmacêutica e equidade. Cad Saude Publica. 2009;25(8):1839-49. DOI:10.1590/S0102-311X2009000800020        [ Links ]

5 Cruz RN, Correia MOG. Teoria dos Sistemas de Niklas Luhmann e os desafios para a efetivação jurisdicional do Direito à Saúde em matéria de medicamentos. RECIIS. 2007;1(2):262-72. DOI:10.3395/reciis.v1i2.93pt        [ Links ]

6. Fontanella BJB, Ricas J, Turato ER. Amostragem por saturação em pesquisas qualitativas em saúde: contribuições teóricas. Cad Saude Publica. 2008;24(1):17-27. DOI:10.1590/S0102-311X2008000100003        [ Links ]

7. Hogerzeil HV, Samson M, Casanovas JV, Rahmani-Ocora L. Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts? Lancet. 2006;368(9532):305-11. DOI:10.1016/S0140-6736(06)69076-4        [ Links ]

8. Kunzler CM. A teoria dos sistemas sociais de Niklas Luhmann. Estud Sociol. 2004;16:123-36.         [ Links ]

9. Lefèvre F, Lefèvre AMC. O discurso do sujeito coletivo: um novo enfoque em pesquisa qualitativa. Caxias do Sul: Educs; 2005.         [ Links ]

10. Luhmann N. La sociedad de la sociedad. México: Herder; 2007.         [ Links ]

11. Machado MAA, Acurcio FA, Brandão CMR, Faleiros DR, Guerra Jr AA, Cherchiglia ML, et al. Judicialização do acesso a medicamentos no Estado de Minas Gerais, Brasil. Rev Saude Publica. 2011;45(3):590-8. DOI:10.1590/S0034-89102011005000015        [ Links ]

12. Marques SB, Dallari SG. Garantia do direito social à assistência farmacêutica no Estado de São Paulo. Rev Saude Publica. 2007;41(1):101-7. DOI:10.1590/S0034-89102007000100014        [ Links ]

13. Pepe VLE, Castro CGSO, Luiza VL. Relação Nacional de Medicamentos Essenciais: um instrumento da Política Nacional de Medicamentos na garantia do acesso. In: Buss PM, Carvalheiro JR, Casas CP, editores. Medicamentos no Brasil: Inovação e Acesso. Rio de Janeiro: Editora Fiocruz; 2008. p.328.         [ Links ]

14. Proner C. Propriedade Intelectual e direitos humanos: Sistema Internacional de Patentes e Direito ao Desenvolvimento. Porto Alegre: Sérgio Antônio Fabris; 2007.         [ Links ]

15. Reis ALA, Bermudez JAZ. Aspectos econômicos: mercado farmacêutico e preços de medicamentos. In: Bermudez JAZ, Oliveira MA, Esher A, editores. Acceso a Medicamentos: Derecho fundamental, papel del Estado. Rio de Janeiro: Editora Fiocruz; 2004. p.144-50.         [ Links ]

16. Rovira J. Intellectual property right and pharmaceutical development. In: Costa-Font J, Courbage C, MCGuire A, editores. The economics of New health technologies. New York: Oxford University Press; 2009, p.232-33.         [ Links ]

17. Schwartz G. O tratamento jurídico do risco no direito à saúde. Porto Alegre: Livraria do Advogado Editora; 2004.         [ Links ]

18. Serra-Sastre V, McGuire A. Diffusion of health Technologies: evidence from the pharmaceutical sector. In: Costa-Font J. Courbage C. McGuire A, editors. The economics of New health technologies. New York: Oxford University Press; 2009. p.58-61.         [ Links ]

19. Tachinardi M H. A guerra das Patentes: O conflito Brasil x EUA sobre propriedade intelectual. Rio de Janeiro: Paz e Terra; 1993.         [ Links ]

20. Timm LB. Qual a maneira mais eficiente de prover direitos fundamentais: uma perspectiva de direito e economia? In: Sarlet IW, Timm LB, editores. Direitos fundamentais, orçamento e "reserva do possível". Porto Alegre: Livraria do Advogado; 2008. p.55-67.         [ Links ]

21. Vieira FS, Zucchi P. Distorções causadas pelas ações judiciais à política de medicamentos no Brasil. Rev Saude Publica. 2007;41(2):214-22. DOI:10.1590/S0034-89102007000200007        [ Links ]

22. Wang DWL. Escassez de recursos, custos dos direitos e reserva do possível na jurisprudência do Supremo Tribunal Federal. Rev Direito GV. 2008;4(2):539-68. DOI:10.1590/S1808-24322008000200009        [ Links ]

 

 

Correspondence:
Artur Stamford
Rua do Hospício, 371, bloco C, 2º andar
Boa Vista 50050-050
Recife, PE, Brasil
E-mail: artur.silva@ufpe.br

Receveid: 9/4/2011
Approved: 4/1/2012

 

 

The authors declare that there are no conflicts of interest. Study based on the master's degree dissertation of Maísa Cavalcanti Pereira presented to the Universidade Federal de Pernambuco in 2011.
a United Nations. International Covenant on Economic, Social and Cultural Rights. Geneva;1996 [cited 2011 Jun 22]. Available from: http://www2.ohchr.org/english/law/pdf/cescr.pdf
b Ministério da Saúde. Secretaria de Políticas de Saúde. Projeto Promoção da Saúde. Declaração de Alma-Ata. In: Conferência Internacional sobre cuidados primários de saúde; 2001; Brasília, BR. p.15. (a) Circularity of the communication elements, creating a recursive self-referential network; (b) Direction determined from the binary code. Maintenance of the direction is represented in the circularity of the elements by a dark shade. Change in the direction is represented in the circularity of the elements by a light shade; (c) Structural linkage, allowing reciprocal stimuli between different social systems.
c IPharm Exec. We leap tall buildings to bring you the definitive guide to the world's top pharma companies. Pharm Exec. 2009 May [cited 2011 Jul 22]:68-79. Available from: http://pharmexec.findpharma.com/pharmexec/data/articlestandard//pharmexec/ 352009/621548/article.pdf
d Instituto de Pesquisa Econômica e Aplicada. Brasil chega a PIB per capita de US$ 10 mil em 2010. E agora? Brasília; 2010 [cited 2011 Jul 23]. Available from: http://www.ipea.gov.br/portal/index.php?option=com_content&view=article&id=2036& Itemid=75
e Instituto Brasileiro de Geografia e Estatística. Pesquisa de Orçamento Familiar (POF) 2008/2009 mostra desigualdades e transformações no orçamento das famílias brasileiras. Brasília; 2010 [cited 2011 Jul 10]. Available from: http://www.ibge.gov.br/home/presidencia/noticias/noticia_visualiza.php?id_noticia= 1648&id_pagina=1 (1) Political system. 2) Scientific System. (3) Economic system. (4) Legal system. (a) Circularity of the communication elements, creating the recursive self-referential network. (b) Direction created from the binary code with positive and negative versions. (c) Structural linkages (Federal Constitution and laws, intellectual property and scientific knowledge), allowing reciprocal stimuli between these social systems.
f Scheffer MC. Aids, tecnologia e acesso sustentável a medicamentos: a incorporação dos anti-retrovirais no Sistema Único de Saúde [doctoral thesis]. São Paulo: Faculdade de Medicina da USP; 2008 [cited 2011 Jun 20]. Available at: http://www.teses.usp.br/teses/disponiveis/5/5137/tde-08072008-133201/pt-br.php
g Bomfim RLD. Agenda única de saúde: a busca do acesso universal e a garantia do direito à saúde [doctoral thesis]. Rio de Janeiro: UERJ; 2008 [cited 2011 Jun 20]. Available at: http://www.tesesims.uerj.br/lildbi/docsonline/get.php?id=533